In a report released today, Matt Phipps from William Blair reiterated a Buy rating on Tempest Therapeutics (TPST – Research Report). The ...
In a regulatory filing, Prelude Therapeutics (PRLD) disclosed that its CEO Krishna Vaddi bought 675K shares of common stock on March 25th in a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback